Medicus Pharma(MDCX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Medicus Pharma
MDCX.US
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.
1.955 T
MDCX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BUZZ-Medicus Pharma gains after cutting royalty payment to Teverelix

    Medicus Pharma's shares rose 12% to $1.49 in premarket trading after the company announced a reduction in royalty payments for its prostate cancer drug, teverelix, from approximately 4% to 2% following a deal amendment with LifeArc. The drug is currently in trials for advanced prostate cancer and urinary retention. Medicus plans mid-stage testing and anticipates early data for its SkinJect skin cancer patch by early 2026. However, shares have declined about 37% in 2025.

    Reuters·
    US
    MDCX
    +0.75%
    Reuters·
    US
    MDCX
    +0.75%

    Antev Ltd. Secures Reduced Royalty Deal to Boost Teverelix Economic Profile

    Antev Ltd., a subsidiary of Medicus Pharma, has amended its license with LifeArc, resulting in a reduced royalty rate for Teverelix to 2%. This strategic move aims to enhance the economic profile of Teverelix.

    Reuters·
    US
    MDCX
    +0.75%
    Reuters·
    US
    MDCX
    +0.75%

    Medicus Pharma Ltd. marked one year on Nasdaq with AI drug development, multiple Phase 2 Catalysts, and SKNJCT-003 study progress.

    As we move into 2026, the Company is equipped with numerous Phase 2 Catalysts and an AI-driven approach to drug development. Additionally, there is regulatory flexibility as we near the database lock, topline clinical data disclosure, and preparation for potential partnerships in relation to the SKNJCT-003 study.

    Unusual Whales·
    US
    MDCX
    +0.75%
    Unusual Whales·
    US
    MDCX
    +0.75%

    Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones

    Medicus Pharma Ltd (MDCX) announced positive Phase 1 data for its GnRH antagonist Teverelix, showing effective hormone suppression and a favorable safety profile. The data will be presented at the 2026 American Association of Clinical Endocrinology meeting, supporting its use in women's health and prostate cancer. Additionally, the SkinJect™ Phase 2 trial has completed enrollment, with results expected in early 2026. Analysts rate MDCX stock as a Hold with a $1.50 price target, citing weak financial performance and bearish technicals.

    Tip Ranks·
    US
    MDCX
    +0.75%
    Tip Ranks·
    US
    MDCX
    +0.75%

    Medicus Pharma Completes Phase 2 Enrollment for SkinJect Basal Cell Carcinoma Study

    Medicus Pharma Ltd. has completed enrollment of 90 patients for its Phase 2 clinical trial of SkinJect™, a treatment for basal cell carcinoma. Topline data is expected in Q1 2026, with an End-of-Phase 2 meeting with the FDA planned for the first half of 2026. Preliminary findings show over 60% clinical clearance, but final results are yet to be determined. This news is generated by Public Technologies and should not be considered financial or legal advice.

    Reuters·
    US
    MDCX
    +0.75%
    Reuters·
    US
    MDCX
    +0.75%
    © 2026 Longbridge｜Disclaimer